1

Dechra Pharmaceuticals

#2371

Rank

$5.44B

Marketcap

GB United Kingdom

Country

Dechra Pharmaceuticals
Leadership team

Mr. Ian D. Page (CEO, MD & Exec. Director)

Mr. Paul Nicholas Sandland MAAT, FCCA (CFO & Exec. Director)

Dr. Anthony Gerard Griffin (MD of Dechra Veterinary Products for Europe & Exec. Director)

Products/ Services
Biotechnology, Pharmaceutical, Veterinary
Number of Employees
1,000 - 20,000
Headquarters
Cheshire, Connecticut, United States
Established
1997
Net Income
20M - 100M
Revenue
500M - 1B
Traded as
DPH.L
Social Media
Overview
Location
Summary
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. In addition, the company distributes veterinary pharmaceuticals and equipment; offers financial services; markets pet diets; and develops, regulates, manufactures, and markets crop protection. It markets its products through wholesaler and distributor networks. The company operates in the United Kingdom, Germany, rest of Europe, the United States, and internationally. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.
History

The Company was founded in 1997 by way of a management buy-out from Lloyds Chemists. It was first listed on the London Stock Exchange in 2000. In 2007 it bought VetXX, a Danish veterinary products business, for £62 million. In 2010 it purchased Florida-based DermaPet for US$64 million and Sussex-based Genitrix for £5 million.It sold its veterinary services business to US-firm, Patterson Companies, for £87.5m in July 2013 in order to focus on its higher margin manufacturing business.

Mission
Dechra Pharmaceuticals PLC is committed to providing quality animal health products and services to our customers and the development of innovative solutions in animal health.
Vision
To be the first-choice partner and supplier of innovative, reliable and quality animal health products and services with the highest ethical standards.
Key Team

Mr. Patrick Meeus (Group Scientific Officer)

Ms. Katy Clough (Group HR Director)

Mr. Mike Eldred (Pres of North America)

Ms. Melanie Hall (Company Sec.)

Recognition and Awards
Dechra Pharmaceuticals was named Company of the Year at the London Stock Exchange Group's 2016 Investor and Adviser Awards.
References
Dechra Pharmaceuticals
Leadership team

Mr. Ian D. Page (CEO, MD & Exec. Director)

Mr. Paul Nicholas Sandland MAAT, FCCA (CFO & Exec. Director)

Dr. Anthony Gerard Griffin (MD of Dechra Veterinary Products for Europe & Exec. Director)

Products/ Services
Biotechnology, Pharmaceutical, Veterinary
Number of Employees
1,000 - 20,000
Headquarters
Cheshire, Connecticut, United States
Established
1997
Net Income
20M - 100M
Revenue
500M - 1B
Traded as
DPH.L
Social Media